Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ARS Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

ARS Pharmaceuticals' CEO'su Rich Lowenthal, Nov2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 10.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.2% maaş ve 93.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.89% ine doğrudan sahiptir ve bu hisseler $ 82.82M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 3.2 yıldır.

Anahtar bilgiler

Rich Lowenthal

İcra Kurulu Başkanı

US$10.0m

Toplam tazminat

CEO maaş yüzdesi	6.2%
CEO görev süresi	1.9yrs
CEO sahipliği	5.9%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

CEO Tazminat Analizi

Rich Lowenthal'un ücretlendirmesi ARS Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$10m	US$620k	-US$54m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$909k	US$75k	-US$35m

Tazminat ve Piyasa: Rich 'nin toplam tazminatı ($USD 10.04M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).

Tazminat ve Kazançlar: Rich şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Rich Lowenthal (58 yo)

1.9yrs

Görev süresi

US$10,039,096

Tazminat

Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, He serves as Director, Chief Executive Officer & President at ARS Pharmaceuticals, Inc. since November 08, 2022. He served as Head of Regulatory...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Lowenthal	Founder	1.9yrs	US$10.04m	5.89% $ 81.1m
Sarina Tanimoto	Co-Founder & Chief Medical Officer	no data	US$4.79m	3.52% $ 48.4m
Alexander Fitzpatrick	Chief Legal Officer & Secretary	1.8yrs	US$5.32m	0.092% $ 1.3m
Robert Bell	Co-Founder & Chief Science Officer	no data	Veri yok	4.35% $ 59.8m
Kathleen Scott	Chief Financial Officer	2.5yrs	Veri yok	0.014% $ 187.4k
Brian Dorsey	Chief Operations Officer	no data	Veri yok	0.0062% $ 85.4k
Daniel Relovsky	Senior Vice President of Marketing	2.7yrs	Veri yok	Veri yok
Harris Kaplan	Executive Vice President of Commercial Strategy	2.7yrs	Veri yok	Veri yok
Eric Karas	Chief Commercial Officer	2.5yrs	US$618.61k	0.0059% $ 80.7k
Justin Chakma	Chief Business Officer & Secretary	1.9yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: SPRY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Lowenthal	Founder	1.9yrs	US$10.04m	5.89% $ 81.1m
Phillip Schneider	Independent Director	no data	US$261.30k	0% $ 0
Pratik Shah	Chairman of the Board	no data	US$508.80k	4.98% $ 68.5m
Brenton L. Saunders	Director	3.4yrs	US$238.80k	0% $ 0
Rajeev Dadoo	Independent Director	3.2yrs	US$256.30k	Veri yok
Peter Kolchinsky	Independent Director	3.2yrs	US$253.80k	Veri yok
Saqib Islam	Independent Director	1.9yrs	US$250.05k	0.016% $ 216.2k
Thomas Casale	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Kaliner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Motohiro Ebisawa	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Kelly	Independent Director	no data	US$248.80k	0.086% $ 1.2m
Richard Lockey	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SPRY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

ARS Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Recent updates

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

ARS Pharmaceuticals, Inc. Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Approval of EURneffy (adrenaline nasal spray) in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)

Consensus revenue estimates decrease by 19%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study

New minor risk - Profitability

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Consensus EPS estimates upgraded to US$0.64 loss

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Consensus revenue estimates decrease by 99%, EPS upgraded

ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

Consensus revenue estimates fall by 67%

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Chief Financial Officer recently bought US$52k worth of stock

No independent directors

ARS Pharmaceuticals, Inc. Announces Presentation of Clinical Data Supporting Neffy® for the Treatment of Allergic Reactions (Type I) Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Board Changes

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş